Clinical Rheumatology

, Volume 30, Issue 7, pp 1007–1012 | Cite as

Infliximab for patients with neuro-Behcet's disease: case series and literature review

  • Afshin Borhani HaghighiEmail author
  • Anahid Safari
  • Mohammad Ali Nazarinia
  • Zahra Habibagahi
  • Saeedeh Shenavandeh
Case Based Review


This study aims to report the therapeutic effects of anti-tumor necrotic factor antibody, infliximab, for treatment of neuro-Behcet's disease (NBD) and to review the literature. We described four patients (all male, median age 40 years old) who fulfilled the International Study Group criteria for Behcet's disease (BD) and presented with neurological complication. Demographic and clinical characteristics of the patients, dose, therapeutic effects, and adverse drug reaction (ADR) of infliximab were reported. Two patients had secondary progressive, one relapsing progressive, and one primary progressive course (median duration of BD and NBD 11 and 2 years, respectively). Two patients each received infliximab with 3 and 5 mg/kg infusions, respectively. The patients received infliximab for median of 22 weeks. Clinical responses were unsatisfactory for two patients on 3 mg/kg regimen; and good in two patients on 5 mg/kg and monthly intravenous 500–1,000 mg cyclophosphamide. Varicella zoster infection was seen as a major ADR in one patient. Our results with infliximab were not as promising as the previous reports. Infliximab, 5 mg/kg per dose with adjuvant immunosuppressive therapy, is probably more effective than other regimens.


Anti-tumor necrotic factor antibody Behcet syndrome Behcet's disease Infliximab Neuro-Behcet's disease 



Tumor necrotic factor


Cerebrospinal fluid












Cyclosporine A






Intravenous methylprednisolone





  1. 1.
    Borhani Haghighi A, Pourmand R, Nikseresht AR (2005) Neuro-Behcet disease: a review. Neurologist 11:80–89PubMedCrossRefGoogle Scholar
  2. 2.
    Borhani-Haghighi A, Samangooie S, Ashjazadeh N, Nikseresht A, Shariat A, Yousefipour G, Safari A (2006) Neurological manifestations of Behcet's disease. Saudi Med J 27:1542–1546PubMedGoogle Scholar
  3. 3.
    Borhani Haghighi A (2009) Treatment of neuro-Behcet's disease: an update. Expert Rev Neurother 9:565–574PubMedCrossRefGoogle Scholar
  4. 4.
    Arida A, Fragiadaki K, Giavri E, Sfikakis PP (2010) Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum. doi: 10.1016/j.semarthrit.2010.09.002
  5. 5.
    International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. (1990) Lancet 335:1078–1080Google Scholar
  6. 6.
    Borhani Haghighi A, Safari A (2008) Anti-tumor necrotic factor antibody for treatment of neuro-Behcet's disease, a case report. Clin Neurol Neurosurg 110:315–316PubMedCrossRefGoogle Scholar
  7. 7.
    Licata G, Pinto A, Tuttolomondo A, Banco A, Ciccia F, Ferrante A, Triolo G (2003) Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behcet's syndrome. Ann Rheum Dis 62:280–281PubMedCrossRefGoogle Scholar
  8. 8.
    Sarwar H, McGrath H Jr, Espinoza LR (2005) Successful treatment of long-standing neuro-Behcet's disease with infliximab. J Rheumatol 32:181–183PubMedGoogle Scholar
  9. 9.
    Ribi C, Sztajzel R, Delavelle J, Chizzolini C (2005) Efficacy of TNF(alpha) blockade in cyclophosphamide resistant neuro-Behcet disease. J Neurol Neurosurg Psychiatr 76:1733–1735PubMedCrossRefGoogle Scholar
  10. 10.
    Alty JE, Monaghan TM, Bamford JM (2007) A patient with neuro-Behcet's disease is successfully treated with etanercept: further evidence for the value of TNFalpha blockade. Clin Neurol Neurosurg 109:279–281PubMedCrossRefGoogle Scholar
  11. 11.
    Fujikawa K, Aratake K, Kawakami A, Aramaki T, Iwanaga N, Izumi Y, Arima K, Kamachi M, Tamai M, Huang M, Nakamura H, Nishiura Y, Origuchi T, Ida H, Eguchi K (2007) Successful treatment of refractory neuro-Behcet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile. Ann Rheum Dis 66:136–137PubMedCrossRefGoogle Scholar
  12. 12.
    Belzunegui J, Lopez L, Paniagua I, Intxausti JJ, Maiz O (2008) Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behcet's disease. Clin Exp Rheumatol 26:S133–S134PubMedGoogle Scholar
  13. 13.
    Pipitone N, Olivieri I, Padula A, D'Angelo S, Nigro A, Zuccoli G, Boiardi L, Salvarani C (2008) Infliximab for the treatment of neuro-Behcet's disease: a case series and review of the literature. Arthritis Rheum 59:285–290PubMedCrossRefGoogle Scholar
  14. 14.
    Madanat WY, Madanat AY (2008) Worsening of osteomalacia in a patient successfully treated for neuro-Behcet's disease with infliximab. Clin Exp Rheumatol 26:S128–S129PubMedGoogle Scholar
  15. 15.
    Kikuchi H, Aramaki K, Hirohata S (2008) Effect of infliximab in progressive neuro-Behcet's syndrome. J Neurol Sci 272:99–105PubMedCrossRefGoogle Scholar
  16. 16.
    Kikuchi H, Asako K, Takayama M, Arinuma Y, Hirohata S (2010) Infliximab therapy for chronic progressive neuro-Behcet's disease: a four-year follow-up study. Clin Exp Rheumatol 28:S147–S147Google Scholar
  17. 17.
    Abalos-Medina GM, Sanchez-Cano D, Ruiz-Villaverde G, Ruiz-Villaverde R, Quirosa Flores S, Raya Alvarez E (2009) Successful use of infliximab in a patient with neuro-Behcet's disease. Int J Rheum Dis 12:264–266PubMedCrossRefGoogle Scholar
  18. 18.
    Matsui T, Ishida T, Tono T, Yoshida T, Sato S, Hirohata S (2010) An attack of acute neuro-Behçet's disease during the course of chronic progressive neuro-Behçet's disease: report of two cases. Mod Rheumatol 20:621–626PubMedCrossRefGoogle Scholar
  19. 19.
    Al-araji A, Saip ASS, Constantinescu C, Akman-demir G, Arayssi T, Espinoza L, Findling O, Garcia F, Hirohata S, Keogan M, Lo Monaco A, Pay S, Ramo C, Van Laar J, Zandi M (2010) Treatment of neuro-Behcet's disease with infliximab. An International Multicentre Case-Series of 18 patients. Clin Exp Rheumatol 28:S119–S119Google Scholar
  20. 20.
    Sfikakis PP, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A, Ohno S, Pipitone N, Schirmer M, Stanford M, Wechsler B, Zouboulis C, Kaklamanis P, Yazici H (2007) Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations. Rheumatology (Oxford) 46:736–741CrossRefGoogle Scholar
  21. 21.
    Alpsoy E, Akman A (2009) Behcet's disease: an algorithmic approach to its treatment. Arch Dermatol Res 301:693–702PubMedCrossRefGoogle Scholar
  22. 22.
    Borhani Haghighi A, Safari A (2010) Proposing an algorithm for treatment of different manifestations of neuro-Behcet's disease. Clin Rheumatol 29:683–686PubMedCrossRefGoogle Scholar
  23. 23.
    Lanthier N, Parc C, Scavennec R, Dhote R, Brezin AP, Guillevi L (2005) Infliximab in the treatment of posterior uveitis in Behcet's disease. Long term follow up in four patients. Presse Méd 34:916–918PubMedCrossRefGoogle Scholar
  24. 24.
    Borhani Haghighi A, Sarhadi S, Farahangiz S (2010) MRI findings of neuro-Behcet's disease. Clin Rheumatol. doi: 10.1007/s10067-010-1650-9
  25. 25.
    Akman-Demir G, Serdaroglu P, Tasci B (1999) Clinical patterns of neurological involvement in Behcet's disease: Evaluation of 200 patients. Brain 122(Pt 11):2171–2182PubMedCrossRefGoogle Scholar
  26. 26.
    Ideguchi H, Suda A, Takeno M, Kirino Y, Ihata A, Ueda A, Ohno S, Baba Y, Kuroiwa Y, Ishigatsubo Y (2010) Neurological manifestations of Behcet's disease in Japan: a study of 54 patients. J Neurol 257:1012–1020PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2011

Authors and Affiliations

  • Afshin Borhani Haghighi
    • 1
    • 2
    • 3
    Email author
  • Anahid Safari
    • 4
  • Mohammad Ali Nazarinia
    • 5
  • Zahra Habibagahi
    • 5
  • Saeedeh Shenavandeh
    • 5
  1. 1.Transgenic Technology Research CenterShiraz University of Medical SciencesShirazIran
  2. 2.Departments of NeurologyShiraz University of Medical SciencesShirazIran
  3. 3.Department of Neurology and PsychiatrySaint Louis UniversitySaint LouisUSA
  4. 4.Research Center for Traditional Medicine and History of MedicineShiraz University of Medical SciencesShirazIran
  5. 5.Division of Rheumatology, Departments of Internal MedicineShiraz University of Medical SciencesShirazIran

Personalised recommendations